Magdalena Mileva, MD, PhD, is a nuclear medicine specialist at the University Hospital Brussels, Belgium. Her primary clinical and research focus is radiopharmaceutical therapy for neuroendocrine neoplasms. She completed her PhD at ULB (Université libre de Bruxelles), where her research focused on peptide receptor radionuclide therapy (PRRT) for neuroendocrine tumours, with particular emphasis on treatment efficacy and outcome prediction using multimodality imaging and dosimetry.

Dr. Mileva has presented her research at numerous national and international congresses and scientific conferences and has received several awards in recognition of her work. She has authored and co-authored multiple peer-reviewed publications in the field of nuclear medicine and neuroendocrine tumours. Through her institutional role, she actively participates in international collaborative research initiatives and multicentre clinical trials, contributing to the advancement of radiopharmaceutical therapies and NET research.

Dr Magdalena Mileva has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies: